绿叶制药（02186）今日盘中大跌7.26%，引起市场广泛关注。
消息面上，绿叶制药于3月30日晚间发布了2024年度业绩公告，显示公司业绩出现下滑。公司2024年全年实现收入60.61亿元人民币，同比减少1.33%；股东应占溢利4.72亿元，同比减少11.4%。这一业绩表现不及市场预期，可能是导致股价下跌的主要原因。
值得注意的是，绿叶制药2024年下半年表现不佳，拖累了全年业绩。公司核心产品销售收入也面临下降压力，中枢神经系统、肿瘤、心血管系统及代谢治疗领域产品销售额均出现不同程度下滑。其中，中枢神经系统治疗领域产品销售额减少4.8%，肿瘤治疗领域产品销售额减少1.8%，心血管系统治疗领域产品销售额减少1.6%，代谢治疗领域产品销售额更是下降13.7%。这些因素综合导致了投资者对公司未来发展前景的担忧，进而引发了股价的大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.